It is currently unknown why these fusions are associated with uterine tumors, let alone with new pathogenic subgroups of ESS, but it is intriguing that two of these known JAZF1 fusions (with PHF1 or SUZ12) could directly alter PRC2 function. The gene discussed is JAZF1; the disease is endometrioid stromal sarcoma.